A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine

On 21 January 2021, an interim analysis of a phase-3 clinical trial revealed that the investigational, recombinant-vector COVID-19 vaccine developed by Janssen Pharmaceuticals, Janssen Ad26.COV2.S, was both effective and safe in preventing moderate and severe COVID-19 in adults.1 The vaccine was approved in late February 2021 by the Food and Drug Administration, following Pfizer's BNT162b2 and Moderna's messenger RNA-1273 approval in in December 2020. All 3 vaccines are considered safe by clinical trials.